Bibliographic Details
| Summary: | Abstract Introduction: Obinutuzumab is a type II anti-CD20 monoclonal antibody associated with a higher rate of toxicity when compared to rituximab. Gastrointestinal side-effects have been reported but data is still sparse. Case Presentation: A 47-year-old female with medical history of stage IV follicular non-Hodgkin lymphoma under chemotherapy presented with chronic bloody diarrhea and iron deficiency anemia. Endoscopic and histologic features resembled inflammatory bowel dis-ease (IBD), imposing a thorough differential diagnosis. The diagnosis of obinutuzumab-induced pancolitis was made and the drug was suspended with subsequent clinical improvement. Conclusion: This is the first case report of obinutuzumab-induced pancolitis. The challenging differential diagnosis of IBD required a multi-disciplinary approach with subsequent outcome and management implications. |
|---|
| Main Authors: | Mendes,Raquel R. |
|---|
| Other Authors: | Figueiredo,Pedro C.; Andrade,Isabel |
|---|
| Subject: | Obinutuzumab Colitis Inflammatory bowel disease |
|---|
| Year: | 2024 |
|---|
| Country: | Portugal |
|---|
| Document type: | report |
|---|
| Access type: | open access |
|---|
| Associated institution: | Fundação para a Ciência e Tecnologia |
|---|
| Language: | English |
|---|
| Origin: | SciELO Portugal |
|---|